Clinical Trial · NCT03174054

The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate Lesions

Overview

Prostate cancer is a common disease in men. In prostate 35% of biopsies, usually done due to increased PSA levels or clinical suspicion, are false negative, despite malignancy. Multi-parametric prostate MRI detects malignant neoplasm lesions better than other imaging devices. A sonar-guided prostate biopsy based on multi-parametric MRI images improves detection of malignancy. Ga68 PSMA-PET test uses a radioactive marker that binds to the prostate's cells and is shown to be a primary prostate tumor site in addition to metastasis. We believe that the combination of measures from a single Ga68 PSMA and multi-parametric MRI test can lead to further improvement in malignancy, better biopsy guidance, and optimal treatment for the patient.

Sponsor

Samsung Medical Center

Contacts

David Groshar, MD (CONTACT)

davidg@assuta.co.il

+972-37645497

David Groshar, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03174054

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC
Linker: Ahx

Eligibility

Inclusion

  • Patients with clinical suspicion of prostate cancer, referred for multi parametric MRI

Exclusion

  • Are unable to perform multi-parameter MRI (eg GFR below 30, metals in the body, claustrophobia, etc.).